TLDR
- Amgen shares climbed approximately 4% during premarket hours Tuesday following encouraging Phase 3 data for dazodalibep in treating Sjögren’s disease
- The OASIZ 301 clinical trial achieved its primary goal, demonstrating statistically significant enhancement in overall disease activity by Week 48
- Patient benefits emerged as quickly as Week 4 and persisted throughout the entire 48-week trial duration
- No FDA-approved medications currently exist for Sjögren’s disease, positioning dazodalibep as a potentially groundbreaking first-in-class treatment option
- Complete trial findings will be shared at an upcoming medical gathering; an additional Phase 3 trial is projected to conclude in the fourth quarter of 2026
Amgen (AMGN) shares surged approximately 4% during early Tuesday trading, reaching $406.02 shortly after market open, following the biotechnology company’s announcement of encouraging topline findings from its Phase 3 clinical trial examining dazodalibep, an investigational treatment for Sjögren’s disease.
The clinical study, designated OASIZ 301, successfully achieved its primary goal. Participants demonstrated statistically significant enhancement in overall disease activity by Week 48, as assessed using the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI).
This upward momentum propelled AMGN shares back above their 50-day moving average threshold.
The clinical investigation recruited approximately 621 participants diagnosed with moderate-to-severe systemic Sjögren’s disease. Findings revealed patient improvements beginning at Week 4, with these benefits maintained throughout the entire 48-week trial duration.
Sjögren’s represents a systemic autoimmune condition characterized by dryness symptoms, exhaustion, persistent pain, and potential major organ involvement. Currently, no FDA-sanctioned medications exist for managing this condition.
This therapeutic void represents a significant commercial opportunity. Should dazodalibep successfully navigate regulatory scrutiny, it would become the inaugural approved medication for Sjögren’s disease.
Understanding Dazodalibep’s Mechanism
Dazodalibep functions as a CD40L antagonist fusion protein. Its therapeutic action involves blocking the cellular communications between T cells, B cells, and additional immune system components that perpetuate the disease process.
Jay Bradner, Amgen’s executive vice president of research and development, noted that both the rapid onset and sustained nature of the outcomes strengthened the organization’s belief in the therapeutic agent and its comprehensive Phase 3 development program.
The trial’s most frequently observed adverse events included nasopharyngitis, urinary tract infections, elevated blood pressure, and reactions related to infusion. The majority were categorized as mild to moderate in severity. Patient withdrawal rates attributed to adverse effects remained minimal and comparable between active treatment and placebo cohorts.
Market Competition Analysis
Amgen faces competition in this therapeutic area. Novartis (NVS) is concurrently advancing ianalumab, a Sjögren’s treatment candidate that operates through a distinct mechanism by targeting the BAFF protein.
Ianalumab demonstrated 1.3- to 1-point superior results compared to placebo on a 42-point symptom assessment scale in its clinical evaluation. Leerink Partners analyst David Risinger indicated the therapy appears positioned for regulatory approval within the next several months.
Risinger maintains a market perform rating on AMGN shares.
Amgen intends to share comprehensive OASIZ 301 data at a forthcoming medical conference. This detailed disclosure will enable investors to better evaluate dazodalibep’s comparative performance against ianalumab.
An additional Phase 3 investigation, OASIZ 303, is evaluating dazodalibep in individuals with moderate-to-severe symptomatic Sjögren’s disease. This trial is anticipated to reach completion during Q4 2026.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
